

Shinichiro Takahashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4707234/publications.pdf>

Version: 2024-02-01

18
papers

1,088
citations

759055

12
h-index

839398

18
g-index

18
all docs

18
docs citations

18
times ranked

1585
citing authors

#	ARTICLE	IF	CITATIONS
1	Noadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2022, 276, e510-e517.	2.1	33
2	Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. <i>Scientific Reports</i> , 2020, 10, 18278.	1.6	29
3	Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer. <i>BMC Cancer</i> , 2020, 20, 1184.	1.1	3
4	Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. <i>Cancer Science</i> , 2020, 111, 334-342.	1.7	13
5	Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. <i>Cancer Science</i> , 2020, 111, 2747-2759.	1.7	19
6	Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radical surgery. <i>Oncology Letters</i> , 2020, 19, 2657-2666.	0.8	9
7	Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2019, 9, 17145.	1.6	15
8	Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JJAP-05).. <i>Journal of Clinical Oncology</i> , 2019, 37, 189-189.	0.8	185
9	Measure of pancreas transection and postoperative pancreatic fistula. <i>Journal of Surgical Research</i> , 2016, 202, 276-283.	0.8	6
10	Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. <i>Oncolmmunology</i> , 2016, 5, e1129483.	2.1	125
11	Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. <i>International Journal of Oncology</i> , 2012, 40, 63-70.	1.4	54
12	Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival. <i>Clinical Cancer Research</i> , 2012, 18, 3686-3696.	3.2	246
13	Clinicopathological features of stomach cancer with invasive micropapillary component. <i>Gastric Cancer</i> , 2012, 15, 179-187.	2.7	24
14	Evaluation of the Prognostic Factors and Significance of Lymph Node Status in Invasive Ductal Carcinoma of the Body or Tail of the Pancreas. <i>Pancreas</i> , 2010, 39, e48-e54.	0.5	62
15	Relationship Between the Histological Type of Initial Lesions and the Risk for the Development of Remnant Gastric Cancers After Gastrectomy for Synchronous Multiple Gastric Cancers. <i>World Journal of Surgery</i> , 2010, 34, 296-302.	0.8	20
16	Clinical and histopathological features of remnant gastric cancers, after gastrectomy for synchronous multiple gastric cancers. <i>Journal of Surgical Oncology</i> , 2009, 100, 466-471.	0.8	12
17	Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. <i>Cancer Science</i> , 2009, 100, 1403-1407.	1.7	222
18	Adenocarcinoma of the minor duodenal papilla with intraepithelial spread to the pancreatic duct. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 451, 1075-1081.	1.4	11